Metastatic breast adenocarcinomas display activation signatures for signaling pathways that trigger cell motility and tissue invasion. Here, we report that the adaptor protein transducer of Cdc42-dependent actin assembly-1 (Toca-1) is expressed in highly invasive breast cancers and regulates their metastatic phenotypes. We show that Toca-1 localizes to the filamentous actin-rich core of invadopodial protrusions actively degrading the extracellular matrix (ECM). Toca-1 colocalizes with Cortactin, and we show that this interaction is mediated by the SH3 domain of Toca-1. Stable knockdown (KD) of Toca-1 expression in MDA-MB-231 cells led to a significant defect in epidermal growth factor (EGF)-induced cell migration and invasion. Toca-1 KD cells also showed significant defects in EGF-and Src-induced ECM digestion and formation of invadopodial membrane protrusions. To test the role of Toca-1 in metastasis, we achieved stable Toca-1 KD in both human and rat metastatic breast adenocarcinoma cell lines. Orthotopic tumor xenografting of control and Toca-1 KD cells in natural-killer /B-/T-cell-deficient mice revealed a significant defect in spontaneous lung metastases with Toca-1 silencing in vivo. In contrast, no defects in primary tumor growth or lung seeding following tail vein injection of Toca-1 KD cells was observed, suggesting that Toca-1 functions at an early step in the dissemination of metastatic breast tumor cells. Taken together, our results identify Toca-1 as a proinvasive protein in breast adenocarcinoma and a potential therapeutic target to limit tumor metastasis.
INTRODUCTION
The metastatic spread of breast cancer is the leading cause of breast cancer deaths, and spread to the lymph nodes is considered one of the earliest clinical indications that a breast tumor has a propensity for metastasis. 1, 2 Among the breast cancer subtypes, the basal subtype accounts for 10-27% of the breast cancer cases. 3, 4 The common absence of ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) in this subgroup, also called triple negative breast cancer (TNBC), leads to the clinical resistance to conventional therapies and are characterized by aggressive clinical history. 4 TNBC tumors are generally larger in size, are of higher grade, have lymph node involvement at diagnosis and are biologically more aggressive. 5 Recent studies have identified signaling pathways linked to TNBC invasiveness, including epidermal growth factor receptor (EGFR or ErbB1) and Src family protein tyrosine kinases. [6] [7] [8] High EGFR expression in TNBCs is linked to poor prognosis regardless of axillary lymph node involvement and tumor size. 9 Experimental models have shown that EGFR promotes motility, invasion and metastasis of basal breast cancer cells. [10] [11] [12] Highly metastatic cancer cells, including those derived from basal breast tumors, form invadopodia, which are F-actin-based membrane protrusions with extracellular matrix (ECM)-degrading activity. 13, 14 The formation of invadopodia requires signaling from EGFR, integrins, focal adhesion kinase (FAK) and Src kinases that promote recruitment and activation of key actin regulatory proteins and matrix metalloproteases. 15, 16 Epidermal growth factor (EGF)-induced invadopodia formation in basal breast cancer cells requires Cdc42 GTPase and its effector neural Wiskott-Aldrich syndrome protein (N-WASP), which recruit Arp2/3 complex to promote actin branching within invadopodia. 17 This pathway may also involve transducer of Cdc42-dependent actin assembly-1 (Toca-1), as Toca-1 was first identified as an essential factor for Cdc42-dependent recruitment of Arp2/3 complex by the N-WASP/WIP complex in Xenopus extracts. 18 Toca-1 is an adaptor protein composed of the Fer/CIP4 homology-Bin/Amphiphysin/Rvs (F-BAR) domain involved in membrane targeting, a Cdc42-binding homology region 1 (HR1) domain and an SH3 domain that binds proline-rich regions of N-WASP and other proteins. [19] [20] [21] In mammalian cells, Toca-1 and related F-BAR proteins (for example, CIP4, FBP17) regulate endocytosis by inducing F-actin polymerization that promotes membrane scission and vesicle motility. [22] [23] [24] Toca-1 also promotes the formation of F-actin-based membrane protrusions, including filopodia and lamellipodia. 25, 26 Through its SH3 domain, Toca-1 also binds Abi1, a component of the Rac-WAVE pathway, [26] [27] [28] and Diaphanous-related formins. 29, 30 Previous studies have shown that several Toca-1-binding partners are essential for invadopodia formation, including N-WASP, Abi1 and Diaphanous-related formins. 17, 31, 32 Although recent studies implicate CIP4 and FBP17 in regulating invadopodia in breast and bladder cancer cells, [33] [34] [35] the role of Toca-1 in regulating invadopodia has not been reported. We recently reported that Toca-1 is required for maximal EGF-induced cell motility and invasion of A431 epidermoid carcinoma cells. 26 The current study investigates the role of Toca-1 in regulating breast cancer migration, invasion and metastasis. We show that 1 Cancer Biology & Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada and Toca-1 transcript and protein levels are elevated in most luminal and TNBC cell lines compared with normal breast epithelial cell lines. Toca-1 is also expressed in both normal breast tissue, primarily in the ductal epithelium, and in invasive ductal carcinomas. In MDA-MB-231 cells, Toca-1 interacts with actin regulatory proteins, including an SH3 domain-mediated binding to Cortactin. Similarly to Cortactin, Toca-1 localizes within the F-actin core of invadopodia that are actively degrading ECM. To test the function of Toca-1, we used stable silencing of Toca-1 in MDA-MB-231 cells to show that Toca-1 promotes EGF-induced cell migration and invasion by promoting the formation of invadopodia. To study the role of Toca-1 in metastasis, we performed orthotopic xenografting of breast cancer cell lines with a range of metastatic potential. Although Toca-1 silencing had no significant effect on primary tumor growth, we observed a significant reduction in lung metastases. Taken together, these findings identify Toca-1 as a component of invadopodia that promotes cell migration and invasion in vitro and tumor metastasis in vivo. Figure 1a ). To test Toca-1 protein levels, lysates from a similar panel of cell lines were subjected to immunoblot with Toca-1 antisera. Toca-1 levels were lowest in normal breast epithelial HBL-100 cells, at slightly higher levels in luminal cell lines (MCF-7, T47D, SK-BR-3) and at high levels in most TNBC cell lines (Figure 1b ; Actin served as a loading control). Thus, Toca-1 is expressed in human breast epithelial cells and at higher levels in several invasive TNBC cell lines.
RESULTS

Toca
To examine Toca-1 expression in normal human breast tissues and tumors, we performed immunohistochemistry staining of Toca-1 in tissue microarrays. To ensure that the signals correspond to Toca-1 expression, we validated the specificity of rabbit Toca-1 antisera by immunoblot and immunohistochemistry on breast cancer cells and xenograft tumors, with or without Toca-1 silencing (Supplementary Figure 1) . In normal breast tissues, Toca-1 expression was primarily detected in the ductal epithelium, with very low levels in the mammary stroma (Figure 1c ). Invasive ductal carcinomas from patients with lymph node involvement showed a range of Toca-1 expression, with moderate to high expression in 70% of tumors (Figure 1c ). Taken together, these results show that Toca-1 is frequently overexpressed in metastatic breast tumors.
Toca-1 interacts with Cortactin and other actin regulatory proteins in MDA-MB-231 cells To test whether Toca-1 associates with actin regulatory proteins in TNBC cells, and whether EGFR signaling is involved, we chose the well-studied MDA-MB-231 cell line. Cells were treated with or without EGF (5 min) and lysates subjected to immunoprecipitation (IP) with control or Toca-1 antibodies. Several known binding partners of Toca-1 were detected, including Dynamin, Abi1 and N-WASP (Figure 2a ; data not shown). In addition, the p34 Arc subunit of Arp2/3 complex and Cortactin were detected in Toca-1 IPs, but not with control IgG (Figure 2a) . However, EGF treatment had no effect on the levels or recovery of these Toca-1-associated proteins. As Cortactin has not been previously reported to associate with Toca-1, we performed the reciprocal co-IP experiment, and detected Toca-1 in Cortactin IPs, but not those with control IgG (Figure 2b ). These results are consistent with Toca-1 interacting directly or indirectly with Cortactin, a key component of invadopodia in MDA-MB-231 cells. 36 To identify the domains of Toca-1 that contribute to binding of Cortactin, we performed cotransfections of green fluorescent protein (GFP)-tagged Cortactin with red fluorescent protein (RFP)-tagged Toca-1 in HEK293T cells. We observed co-IP of RFP-Toca-1 with GFP-Cortactin and not GFP control (Figure 2c , compare lanes 5 and 6). This interaction was maintained with an HR1 domain mutant (MGD/IST), but lost upon disruption of the SH3 domain (W518K) (Figure 2c , compare lanes 6-8). These differences were not due to altered expression of RFP-Toca-1 mutants or differential recovery of GFP-Cortactin. These results suggest that the SH3 domain of Toca-1 is required for Cortactin binding. To test whether the SH3 domain was sufficient, we performed pull-down assays using lysates from MDA-MB-231 cells that were incubated with beads containing either glutathione-S-transferase (GST) or GST fused to the Toca-1 SH3 domain. Endogenous Cortactin was recovered with the Toca-1 SH3 domain as the bait, compared with Toca-1 promotes breast cancer metastasis H Chander et al minimal recovery with GST control (Figure 2d ). Taken together, these results identify Cortactin as a novel binding partner of Toca-1 (via the SH3 domain), and provides yet another link between Toca-1 and actin regulatory pathways.
Toca-1 localizes to invadopodia in breast cancer cells To study Toca-1 localization in breast cancer cells, MDA-MB-231 cells were cotransfected with Toca-1-RFP and GFP-Cortactin constructs. 25, 37 Phalloidin staining was also performed to visualize F-actin structures. Confocal microscopy revealed Toca-1 localization in the perinuclear region, and in puncta within the cytoplasm and cell periphery (Figure 3a) . Invadopodia form in the perinuclear region of MDA-MB-231 cells, and are marked by F-actin dots, Cortactin and MT1-MMP. 36 Toca-1 showed extensive colocalization with Cortactin and F-actin dots in the perinuclear region ( Figure 3a , see arrows; right panel shows co-localized pixels from all three channels; E30% colocalization of Toca-1, Cortactin and F-actin was observed). The orthogonal views provide further support for colocalization of GFP-Cortactin and RFP-Toca-1 in columns that mostly emanate from the ventral cell surface (Figure 3b , see merge and x-z panels). Given previous studies on Cortactin as a key marker of invadopodia, 36 these results are consistent with Toca-1 localization to invadopodia in breast cancer cells.
To test whether endogenous Toca-1 localizes to invadopodia actively degrading ECM, we used MDA-MB-231 cells expressing activated Src (MDA-Src) that form clusters of invadopodia at the cell periphery, similar to rosettes described for Src-induced podosomes. 33, 36 Toca-1 and Cortactin localization was analyzed by immunofluorescence in MDA-Src cells plated on coverslips coated with fluorescent ECM. Confocal micrographs at the ventral surface of the cells revealed rosettes of invadopodia marked with Cortactin dots at the cell periphery (Figure 3c ). Endogenous Toca-1 was detected within these invadopodia marked with Cortactin, which colocalized with zones of active ECM digestion ( Figure 3d , see x-z and y-z panels). Orthogonal views through a cluster of invadopodia show that Toca-1 partially colocalized with Cortactin in the F-actin-rich core of invadopodia protruding into the ECM (Figure 3d , see high magnification view of x-z panels). Together, these results identify Toca-1 as a novel component of invadopodia, which may contribute to localized activation of actin nucleation promoting factors within these F-actin-rich structures.
Toca-1 promotes invadopodia formation, migration and invasion of breast cancer cells To study the function of Toca-1 in MDA-MB-231 cells, we established stable Toca-1 knockdown (KD) cell pools using two separate short hairpin RNAs (shRNAs) or a control lentiviral vector, as previously described for A431 cells. 26 We observed an almost complete depletion of Toca-1 protein in lysates from MDA-KD1 cells, and partial depletion in MDA-KD2, compared with levels in vector control (MDA-vec) cell lysates ( Figure 4a ). The silencing of Toca-1 did not alter CIP4 or FBP17 expression (data not shown), or EGF-induced tyrosine phosphorylation of EGFR (pY-EGFR; Figure 4b ). As Toca-1 localizes to invadopodia (Figure 3 ), we tested whether Toca-1 silencing alters EGF-induced invadopodia formation in MDA-MB-231 cells. MDA-vec and Toca-1 KD cells were plated on coverslips coated with fluorescent ECM, and treated with or without EGF for 36 h. After performing F-actin staining, epifluorescence micrographs for EGF-treated cells show ; 30% for control and 9% for Toca-1 KD, data not shown). In addition, quantitative analysis of the ECM degradation area per cell revealed a significant defect in Toca-1 KD cells compared with control cells (Figure 4d ). These results suggest that Toca-1 is a positive regulator of invadopodia. As invadopodia promote cell migration and invasion, 36, 38 we tested whether Toca-1 silencing alters these cellular responses. EGF treatment led to increased migration of vector control cells, but significantly less motile cells were detected for Toca-1 KD1 and KD2 cell lines ( Figure 4e ). As both shRNAs used to silence Toca-1 have the same effect, this suggests that the defects are due to Toca-1 silencing and not potential off-target effects. Moreover, the extent of the motility defect correlated with the extent of Toca-1 depletion in KD1 and KD2 cell lines (Figures 4a and e) . As KD1 was most effective, all subsequent experiments were performed comparing vector and KD1 cell pools.
We next examined the contribution of Toca-1 to invasion of MDA-MB-231 cells through a layer of Matrigel (BD Biosciences, Mississauga, ON, Canada) using transwell chambers. EGF treatment of MDA-vec cells promoted their invasion through Matrigel, and this response was significantly reduced in Toca-1 KD cells (Figure 4f ). Taken together, these findings identify Toca-1 as a positive regulator of invadopodia formation or maturation that promotes breast cancer cell migration and invasion.
Toca-1 silencing impairs Src-induced invadopodia in MDA-MB-231 cells To test whether Toca-1 is also functioning in invadopodia induced by activated Src, we performed stable silencing of Toca-1 in MDASrc cells, which showed an almost complete depletion of Toca-1 (Figure 5a ; actin served as a loading control). MDA-Src cells show a more uniformly invasive phenotype, with more invadopodia per cell and more rapid digestion of ECM. 33, 36 MDA-Src vector and Toca-1 KD cells were plated on coverslips coated with fluorescent ECM overnight, followed by staining of F-actin. Epifluorescence micrographs show extensive formation of invadopodia marked by F-actin dots over zones of ECM digestion (Figure 5b ). Although ECM digestion and invadopodia were detected in Toca-1 KD MDA-Src cells (Figure 5b ), there was a significant defect in the percentage of actively degrading cells (Figure 5c ) and in the amount of ECM digestion compared with control cells (Figure 5d ). To ensure that these defects were caused by Toca-1 depletion, we performed rescue experiments by transfecting MDA-Src-KD cells with an shRNA-resistant GFP-Toca-1 plasmid. Compared with transfection with GFP control vector, which showed low levels of ECM digestion, we observed a significant increase in ECM digestion in cells with restored expression of GFP-Toca-1 (Figure 5e, see Figure 5f for quantification). Taken together, these results suggest that Toca-1 signals downstream of EGFR and Src to promote invadopodia formation and/or maturation in breast cancer cells.
Toca-1 promotes formation of invadopodial protrusions As Toca-1 is linked to actin nucleation promoting factor activation pathways, 18, 21 we tested the formation of F-actin-rich invadopodial protrusions through 1-mm pores as recently described. 39 For MDA-Src-vec control cells, we observed frequent formation of invadopodial protrusions through the pores, whereas few pores had invadopodial protrusions in Toca-1 KD cells (Figure 6a ; see arrows). Quantification of these results showed a significant defect in F-actin-based protrusions through pores present below Toca-1 KD cells compared with vector control (Figure 6b ). Similar assays were performed on MDA-vec and MDA-KD cells treated with or without EGF, with similar defects observed upon Toca-1 silencing (data not shown). These results suggest that Toca-1 localization to invadopodia promotes F-actin nucleation pathways to drive or support membrane protrusions. 
Toca-1 promotes breast tumor metastasis to the lungs To investigate contributions of Toca-1 to breast cancer metastasis, we performed mammary fat pad xenografting of control and Toca-1 KD breast cell lines in Rag2 À / À gc À / À mice. A recent study demonstrated that the natural killer cell deficiency in this model is ideal to study spontaneous lung metastases of rat mammary adenocarinoma MTLn3-PL (expressing GFP) and MTLn3-B1 cells (expressing GFP and human EGFR). 40 We performed these experiments with weakly metastatic MDA-MB-231 cells (expressing GFP), moderately metastatic MTLn3-PL cells and highly metastatic MTLn3-B1 cells. Using a similar silencing approach, we achieved an almost complete depletion of rat Toca-1 in MTLn3-PL and MTLn3-B1 cells (Figure 7a ). The vector control and Toca-1 KD cell pools from each cell line were injected into the mammary fat pads of 5-7-week-old female Rag2
À / À gc À / À mice. After 4-5 weeks (4 weeks was optimal for MTLn3-B1 cells, 5 weeks for MTLn3-PL and MDA-MB-231 cells), mammary tumors were removed following euthanasia. We observed no significant defects in tumor mass with Toca-1 KD (Figure 7b ). We also confirmed that Toca-1 silencing was maintained in vivo, as tumor homogenates from Toca-1 KD cells showed a substantial decrease in Toca-1 compared with vector control tumors for each cell system (Supplementary Figure 2) . Further analysis of lung tissues revealed GFP-positive metastases for all three cell lines (Figure 7c) . The numbers and size of the metastases were reduced in lungs from mice injected with Toca-1 KD cells (Figure 7c) . Quantification of these lung metastases revealed a reproducible and significant decrease in metastases in mice injected with Toca-1 KD cells 
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results demonstrate that silencing of Toca-1 renders highly metastatic breast cancer cells less invasive in both cell-based assays and mouse models.
To determine whether Toca-1 KD impairs the ability of breast cancer cells to extravasate and colonize the lung, we performed experimental metastasis assays using MTLn3-B1 vector control and Toca-1 KD cells. Cells were injected into the lateral tail veins of 5-7-week-old female Rag2 À / À gc À / À mice, and 2 weeks later lungs were excised and examined for metastases. Fluorescence micrographs revealed extensive GFP-positive lung metastases for both vector control and Toca-1 KD cells (Supplementary Figure 3) . Quantification of these lung metastases from multiple mice revealed no statistically significant difference between control and Toca-1 KD cells. These results suggest that Toca-1 is not required for seeding or colonization of the lung, and suggest that Toca-1 functions in early steps of tumor cell dissemination.
DISCUSSION
In this study, we report novel findings linking the F-BAR protein Toca-1 to promoting invasion and metastasis of breast adenocarcinomas. Basal-like breast cancers are frequently metastatic, with activated EGFR and Src signaling pathways that induce invadopodia formation and promote metastasis. 10, 12, 40, 41 In this paper, we report that Toca-1 is highly expressed in human breast tumors, and that Toca-1 associates with a number of actin regulatory proteins linked to invadopodia formation. We have identified Cortactin as a novel Toca-1-binding partner (via the SH3 domain of Toca-1), and show that these proteins colocalize within active zones of ECM digestion. Toca-1 localizes to the F-actin/Cortactin-rich core that supports invadopodial protrusions, and likely promotes actin branching in these structures. Toca-1 function in basal breast cancer cells was tested by stable silencing of Toca-1, which impaired EGFinduced migration and invasion through Matrigel. This defect is likely due to reduced EGF-and Src-induced invadopodia in Toca-1 KD cells, leading to impaired ECM digestion. This also correlated with reduced F-actin-based protrusions in Toca-1 KD cells. Interestingly, the stable silencing of Toca-1 was maintained in tumor xenografting studies in mice, and we found that Toca-1 promotes spontaneous metastasis of breast adenocarcinomas from the mammary gland to the lung. This finding was observed for both weakly metastatic and highly metastatic breast adenocarcinoma cell lines. In experimental metastasis assays, Toca-1 silencing had no effect on lung seeding efficiency, suggesting that Toca-1 functions at an early step in tumor metastasis. Collectively, our study identifies Toca-1 as a key node in the pathways promoting invasion and metastasis in breast cancer. 
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As an F-BAR adaptor protein, Toca-1 is likely functioning as a scaffold for directing the recruitment of actin regulatory proteins involved in actin branching and nucleation pathways. 21, 29 As most F-BAR domains induce or stabilize membrane invaginations, 42, 43 the recruitment mechanisms for Toca-1 to membrane protrusions, such as lamellipodia, filopodia or invadopodia, are not well defined 25, 26 (this study). This may be directed by protein-protein interactions with Toca-1, or possibly by F-BAR domain sensing of membrane curvature at the neck of the ventral membrane protrusions. A similar mechanism was recently reported to direct the F-BAR protein Pacsin-2/Syndapin-II to the base of the filopodia. 44 Both Toca-1 and Pacsin-2 induce filopodia formation, 25, 44 which may involve assembly of the branched actin base on which the bundled actin core is polymerized by formins. 29 The precise role of Toca-1 within invadopodia awaits further studies, including the contributions of the F-BAR, HR1 and SH3 domains to its function in actin assembly and localization. In addition, the potential contributions of other F-BAR proteins to the dynamics of membrane remodeling and actin polymerization within invadopodia have begun to emerge in recent studies. [33] [34] [35] FBP17 was identified as a positive regulator of invadopodia in bladder cancer cells, and this required the F-BAR and SH3 domains, which may promote recruitment of Dynamin-2. 35 As FBP17 and Toca-1 are both capable of inducing actin polymerization on curved membranes via activation of the Cdc42/N-WASP/Arp2/3 complex, 23 it is possible that these proteins are partially redundant in their functions. Another component of invadopodia in breast cancer cells is CIP4, which Toca-1 promotes breast cancer metastasis H Chander et al has been reported to have both positive and negative roles in these structures. 33, 34 Pichot et al. 34 reported a loss of invadopodia and defects in migration and invasion in CIP4 KD MDA-MB-231 cells. Our laboratory used a stable silencing of CIP4 in both MDA and MDA-Src cells, which led to increased invadopodia formation and ECM degradation. 33 This inhibitory effect of CIP4 correlated with elevated surface levels of MT1-MMP in CIP4 KD cells, suggesting that CIP4 may regulate invadopodia via internalization of MT1-MMP. 33 A recent study of CIP4 subfamily proteins in actin pepestal formation by enterohemorrhagic E.coli found distinct roles for CIP4, FBP17 and Toca-1. 45 Interestingly, CIP4 inhibited these F-actin-based structures, whereas Toca-1 promoted pedestal formation, 45 which is consistent with our findings for these proteins in invadopodia (Hu et al., 33 and this paper). Further studies using experimental models of breast cancer metastasis, such as the model reported here for Toca-1, should help resolve the contributions of CIP4 to this process.
Our findings identify Toca-1 as a key node in cell invasion and metastasis mechanisms of invasive breast adenocarcinomas. This has important implications for proper regulation of Toca-1 expression levels and for its scaffolding function. It is worth noting that gene expression profiling of breast tumor cells identified Cdc42 and Arp2/3 upregulation in highly invasive cells compared with less invasive cells from the same tumor. 46, 47 These proinvasive proteins likely require Toca-1 to promote metastasis in these tumor cells. Thus, it will be important to test whether Toca-1 expression is also altered in tumor metastases, and how Toca-1 expression levels are controlled in normal epithelial cells and metastatic cancer cells. The recent finding that F-BAR proteins are potentially autoinhibited by their SH3 domains binding to the F-BAR domain 48, 49 provides another potential mode of regulation for this protein family. It will be interesting to determine whether these mechanisms apply to Toca-1, and whether this autoinhibition is lost in highly invasive cancer cells with high levels of active Cdc42 and actin regulatory proteins.
Our study provides the first evidence that Toca-1 has a causal role in tumor metastasis, and is therefore a potential therapeutic target in metastatic breast cancer. As metastasis is the leading cause of cancer-related deaths, it will be important to further characterize this EGFR/Src/Cdc42/Toca-1 signaling pathway in other metastatic cancer models. Our experiments demonstrate that depletion of Toca-1 inhibits spontaneous metastasis of breast adenocarcinomas with low or high metastatic potential. As these basal-like TNBCs are highly aggressive and have worse prognosis compared with other subtypes, 50 alternative therapeutic approaches are needed. Our study identifies Toca-1 as a key node in signaling pathways linked to tumor progression and metastasis. Future studies will be required to develop tools to limit Toca-1 expression or block Toca-1 signaling to actin regulatory proteins in metastatic cancers. This study adds Toca-1 to the growing list of key regulators of invadopodia that promote cell invasion and tumor metastasis. 51 Inhibitors to several components of invadopodia including Src kinase and MT1-MMP have shown promise in preclinical models of breast cancer. 41, 52, 53 
MATERIALS AND METHODS
Antibodies and reagents
Noncommercial antibodies included mouse anti-Toca-1 28 and rabbit anti-CIP4. 33 Commercial antibodies included rabbit anti-Toca-1 (EMD Millipore, Billerica, MA, USA), mouse anti-Cortactin (Upstate Biotech, Lake Placid, NY, USA), rabbit anti-p34-Arc (EMD Millipore), rabbit anti-EGFR (Santa Cruz Biotech, Santa Cruz, CA, USA), mouse anti-active EGFR (BD Biosciences), 54 Toca-1 mRNA levels were first normalized to GAPDH mRNA levels in each sample, and expressed as relative values to that observed for HBL-100 cells (set at 1).
Cell culture and transfections MDA-MB-231 cells and a derivative expressing Src-Y527F (MDA-Src) cells were described previously. 33 Both lines were grown in DMEM supplemented with 10% FBS, 1% antibiotics and 1% glutamine (Invitrogen) at 37 1C in a humidified atmosphere with 5% CO 2 . MTLn3, MTLn3-PL and MTLn3-B1 cells and their culture conditions were described previously Generation of stable Toca-1 KD cell lines Lentiviral transduction of MDA-MB-231, MDA-Src, MTLn3-PL and MTLn3-B1 cells with vector or Toca-1-specific shRNAs was performed essentially as described previously. 26 In MDA cells, KD1 refers to clone 'C12' (5 0 -GAACAG AACTATGCGAAACAA-3 0 ; TRCN0000130069; Open Biosystems, Lafayette, CO, USA), whereas KD2 refers to clone 'D1' (5 0 -CCATTTCTGATGGGACTATCA-3 0 ; TRCN0000130220; Open Biosystems). In MTLn3-PL and MTLn3-B1 cells, Toca-1 KD refers to clone 'C12', which has perfect complementarity to rat Toca-1. Cell pools that survived puromycin selection were propagated for several passages, along with cell pools stably selected with an equal titer of the lentiviral pLKO.1 vector. The efficiency of Toca-1 KD was assessed over several passages by immunoblot using mouse anti-Toca-1 and anti-actin as a loading control. Rescue experiments were performed using a Toca-1 construct (pLVX-puro-based) expressing human Toca-1 with several silent mutations in the C12 shRNA target sequence that we previously described 26 fused at the C-terminus to GFP (pLVX-GFP-puro served as a negative control).
Immunoprecipitation and immunoblotting
To identify Toca-1-associated proteins, MDA-MB-231 cells were starved overnight with serum-free medium before treatment with or without EGF (12.5 nM) for 5 min. Cells were lysed and subjected to IP with mouse antiToca-1 or mouse anti-Cortactin. Following recovery of IP complexes using GammaBind-Sepharose beads (GE Healthcare, Mississauga, ON, Canada), and washing, bound proteins were resolved by SDS-PAGE. Following transfer of proteins to Immobilon P membranes (Millipore) using a semidry transfer method (BioRad), immunoblot with indicated antibodies was carried out followed by appropriate horseradish peroxidase-conjugated secondary antibodies, and detected using enhanced chemiluminescence (Perkin Elmer, Woodbridge, ON, Canada).
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Migration and invasion assays
Invasion assays were performed as described previously. 26 Briefly, transwell inserts (8 mm pore) were coated with 100 ml of ice-cold Matrigel (1:5 dilution in DMEM with 0.5% FBS) for invasion, and coated with 0.1% (w/v) gelatin for migration assays and incubated at 37 1C for 30 min to solidify. A total of 50 000 cells were added in the upper chamber, which was placed in a 24-well plate containing EGF as a chemoattractant. After overnight incubation, the filters were fixed in 4% paraformaldehyde, cells and Matrigel on the top of the filter were removed and the cells attached to the underside of the filter were stained with DAPI. Epifluorescence microscopy was performed to detect nuclei of cells that migrated to the underside of the filters. Scoring of migrating or invading cells from four separate fields was performed for triplicate filters using the Image Pro Plus software (Media Cybernetics, Bethesda, MD, USA).
Colocalization analysis
The Image Pro-Plus software was used for analyzing colocalization of F-actin, Cortactin and Toca-1. Colocalization masks for F-actin/Cortactin were prepared and then overlayed with the Toca-1 channel. Colocalization coefficients were calculated for cotransfected cells (n ¼ 10 cells).
Extracellular matrix degradation assays
MDA-MB-231 vector and Toca-1 KD cells were seeded on gelatin-coated glass coverslips (15 000 cells) containing a layer of TRITC-conjugated fibronectin, prepared as described previously. 33 After incubation for 24-48 h, cells were fixed and stained with F-actin. Epifluorescence microscopy was performed and the areas of ECM digestion underneath the cells stained with F-actin were quantified as digestion area per cell using the Image Pro Plus software. At least 100 cells were quantified for each condition and cell line.
Invadopodium protrusion assay
Invadopodium protrusion assays were performed in 1-mm-pore size Transwell chambers coated with 0.1% gelatin as described. 39 MDA-MB-231, MDA-Src vector and Toca-1 KD cells were starved overnight and then plated in transwells for 24 h (MDA-MB-231 cells) or 16-18 h for MDA-Src cells. Cells were fixed and F-actin stained using Alexa fluor-488 phalloidin to identify protrusions. At least 10 different fields per condition were randomly imaged in each experiment using spinning disk confocal microscopy. Invadopodium protrusions were quantified as the percentage of total pores under the cells contraining F-actin-based protrusions. Orthogonal views and overlay images were prepared using Image Pro Plus.
Immunohistochemistry
Toca-1 expression in human breast tissues and tumors was assessed by immunohistochemistry on human breast tissue microarrays (TMAs; T086b and BR10010a; US Biomax Inc, Rockville, MD, USA) using the LSAB þ System-HRP (Dako, Burlington, ON, Canada). Antigens were retrieved by heating at 94 1C in 10mM sodium citrate, pH 6.0, for 40 min. After peroxidase treatment for 5 min, samples were blocked in TBS/2% goat serum/2% BSA for 30 min and incubated with rabbit anti-Toca-1 antibody (Millipore), diluted 1:100 in blocking buffer for 60 min. The reaction was visualized using the goat anti-rabbit IgG biotinylated linker (Dako) for 20 min followed by Streptavidin-horseradish peroxidase for 20 min and the DAB solution for 3-4 min. Tissues were counterstained with hematoxylin in ammonia water and mounted before imaging by microscopy. Each tumor tissue was analyzed using the H-score system on digitized scans of slides using the Aperio software (Aperio, Vista, CA, USA). The H-score (0-300) is calculated as the sum of the percentage of tumor cells in each intensity category (low, moderate and high Toca-1 expression). 56 Orthotopic tumor xenografting assays
Rag2
À / À gc À / À (BALB/c) mice that are deficient in natural killer, B, and T cells were recently reported to be an optimal model for the detection of lung metastasis from orthotopic mammary tumor xenografts with MTLn3 cells. 40 Animals were housed in a specific pathogen-free facility (Queen's University Animal Care Services), with ventilated cages and sterilized food and water supply. All procedures with mice were approved by the Queen's University Animal Care Committee. Control and Toca-1 KD MDA-MB-231 (transduced with pLVXpuro-EGFP), MTLn3-PL and MTLn3-B1 cells were grown to 70-85% confluence before trypsinization and counting. For xenografting, 1.5 Â 10 6 MDA-MB-231, or 5 Â 10 5 for MTLn3-PL and MTLn3-ErbB1 cells, were injected into the right thoracic mammary fat pads of the Rag2 À / À gc À / À female mice in a volume of 100 ml of 50% Matrigel using a hypodermic syringe. At end points of 4 weeks for MTLn3-B1, or 5 weeks for MTLn3-PL and MDA-MB-231 cells, mice were killed and primary tumor mass recorded. Several tissues were removed for detection of GFP þ metastases, which were primarily observed in the lungs. Lungs were excised, rinsed with cold PBS, placed flat on a microscope slide and imaged with an epifluorescent microscope ( Â 4 objective). The GFP-positive metastases were counted using the Image J software (http:// rsb.info.nih.gov/ij/). The primary tumors and lungs from each mouse were used for histological analysis. Samples were fixed in formalin and embedded in paraffin, and 5 mm sections were stained with hematoxylin and eosin.
Experimental lung metastasis assays
For experimental lung metastasis assays, MDA-MB-231, MTLn3-PL and MTLn3-B1 control and Toca-1 KD cells (2 Â 10 5 ) were injected into the lateral tail veins of 5-7-week-old female Rag2
À / À gc À / À mice. Two weeks later mice were killed, and the lungs were removed and subjected to fluorescent imaging and histological examination.
Statistical analysis
Differences between the control and Toca-1 KD cells were examined for statistical significance (*Po0.05, or **Po0.01) using a paired Student's t-test in Excel (Microsoft, Redmond, WA, USA).
